Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
Industry Spotlights & Insight Articles

In Conversation With... Marta Barisa, Senior Research Fellow at UCL

Edited by Ben Norris | 30 October 2023
Here, we speak to Marta Barisa, Senior Research Fellow at UCL, about switchable CAR-Ts and therapies for solid tumours.
https://www.youtube.com/watch?v=6ucCFKQp7f0

Get your regular dose of industry news and announcements here, and keep up to date with our latest spotlights and updates.

Visit our Cell &Gene Portal to learn more about the latest research into spatial omics and its developments. If you'd like to learn more about Oxford Global's upcoming Cell UK conference, click here to download an agenda or register your interest.

Speaker Biographies

Marta Barisa is a Senior Research Fellow at University College London, and works with the Experimental Paediatric Oncology Research Group and Allogeneic Immunotherapy Research Group at the Zayed Centre of UCL FOS ICH. She specialises in solid cancer immunotherapy development, and has a particular interest in paediatric solid tumours. Her research focuses on evaluating ways to target and re-polarise the solid tumour microenvironment, including approaches in radiotherapy, chemotherapy, checkpoint blockade, and antibody-dependent cellular cytotoxicity. Barisa's work ranges from early-to-late stage cell therapy drug development, including gene engineering construct design, transduction process optimisations, cell signalling analysis, and scale-ups of both viral and cell therapy product manufacture. A key focus for her is the improvement of survival rates for children with high-risk neuroblastoma, providing more effective treatments with fewer side effects.Â

Related Resources

Cell Therapy for Solid Tumors: An Innovative Approach to Cancer Treatment

Cell therapy for solid tumours is an innovative cancer treatment that uses a patient's own immune cells or donor cells to fight cancer, but its effectiveness varies by tumour type and patient's immune system. Although it offers new hope, it poses risks such as cytokine release syndrome and neurotoxicity. Recent advancements have led to better targeting, combination therapies, and next-generation treatments, with future research aimed at improving safety, effectiveness, and accessibility, potentially revolutionising cancer care.
Read More

Advancing Melanoma Treatment: The FDA Gives Lifileucel The Greenlight in Historic Cell & Gene Therapy Breakthrough

The Food and Drug Administration (FDA) approved lifileucel, a one-of-a-kind T-cell therapy developed by Iovance Biotherapeutics for treating melanoma.
Read More

Related Online Activities

Join the conversation with our upcoming Monthly Science Exchanges and Webinars:
01/11/24
Process Challenges in ATMP Development: Overcoming Hurdles for Successful Manufacturing